Meeting
2023 ASCO Annual Meeting
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
Authors
Jihong Liu
Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
Jihong Liu , Yun Zhou , Yili Wang , Jing Wang , ShanBing Wang , Jin Li , Xiaohong Wang , DaPeng Li , Li Wang , Fan Liang , Xianfeng Zhou , Linna Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT05179239
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5529)
DOI
10.1200/JCO.2023.41.16_suppl.5529
Abstract #
5529
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2019 ASCO Annual Meeting
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
First Author: Ronnie Shapira-Frommer
First Author: Ana Oaknin
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou